The nomination committee appointed for the Annual General Meeting 2025.
The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting. The nomination committee’s task is to produce proposals for the AGM regarding […]
Prolight Diagnostics publishes quarterly report Q3, 2024
Financial overviewThird quarter, 1 July – 30 September, Q3 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 3,730 (28) thousand. The profit after tax amounted to SEK -8,795 (-9,755) thousand. Earnings per share before and after dilution: -0.01 […]
Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Last day of trading with warrants of series TO7 in Prolight Diagnostics is today, October 15, 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
The exercise period for warrants of series TO7 in Prolight Diagnostics begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Today, […]
The exercise price for the warrants of series TO7 in Prolight Diagnostics has been determined to SEK 0.12 per share
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight showcases Psyros™ to global key opinion leaders in cardiology at 2024 Cardiac Markers Dialogue Meeting
Prolight Diagnostics today announces its participation at the 2024 Cardiac Markers Dialogue Meeting, on 26th September and 27th September in Glasgow, UK. This prestigious event brings together key opinion leaders including leading researchers and healthcare professionals, to discuss advances in cardiac biomarker diagnostics and their implications for patient care. The 2024 meeting provides an invaluable […]
Prolight Diagnostics publishes half-year report, 2024
Financial overviewSecond quarter, April 1 – June 30, Q2 2024 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to SEK 18 (101) thousand. The profit after tax amounted to SEK -11,224 (-8,033) thousand. Earnings per share before and after dilution: -0.02 […]
Prolight Diagnostics presents the Psyros system at ADLM, one of the world’s largest and most important diagnostics congresses
Prolight Diagnostics (“Prolight”), developer of the Psyros™ digital point-of-care (POC) system for high-sensitivity troponin, announces that the platform will be showcased at DxPxduring the international congress ADLM in Chicago July 28-August 1, 2024. “We are very proud to present the latest commercial instrument prototype and the cartridge that will be used for high-sensitivity troponin assays. […]
Warrants of series TO6 were exercised to approximately 44.8 percent and Prolight Diagnostics receives approximately SEK 9.8 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
